An interventional study of Healthy lifestyle and adherence in Obesity, Diabetes and High Blood Pressure, sponsored by Mexican National Institute of Public Health. Completed at 1 site in Mexico. Open to female participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-11-03.
Sponsored by Mexican National Institute of Public Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 212 studies in Obesity with a site in Mexico — 42 open to participants now, 60 under way, 29 of them phase 3. Obesity · Mexico.
Among the 212 studies in Obesity with a site in Mexico, this one is the 72nd largest by enrollment of the 190 interventional ones that give a count, is one of 5 that started in 2008, is one of 99 with no phase, and was the 41st registered.
11,560 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →42 of the 212 studies in Obesity with a site in Mexico are open now. Recruiting first, the newest first:
Anahuac University · Sites in Mexico
Ages 30–40
Eli Lilly and Company · Sites in Mexico, United States, Belgium and 7 more countries
Ages 6–11
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Sites in Mexico
Ages 18+
Pfizer · Sites in Mexico, United States, Brazil and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Mexico, United States, Argentina and 24 more countries
Ages 18+
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 20 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
212 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 55 · Phase 4 15
First in 2005; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 104 across the 190 interventional studies, 60 across the 21 observational. Of the 115 that completed or were terminated, 17 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 212 have an industry lead sponsor. The 10 most frequent:
Mexican National Institute of Public Health is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Mexican National Institute of Public Health has 6 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
13 of the studies in Obesity with a site in Mexico that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT06439277Phase 3Eli Lilly and CompanyA Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) | 2027-10 |
Add all 13 to your calendar (.ics) → With an account.
Among the 212 studies in Obesity with a site in Mexico, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The metabolic syndrome is a group of cardiometabolic risk factors that reflect a sedentary lifestyle and the excessive intake of food among the risk factors that comprise it are located the obesity, hyperglycemia, dyslipidemia and hypertension.
It has been observed that the interventions of lifestyle changes that promote weight loss through the practice of physical activity and intake of a hypocaloric diet, reduce the prevalence of chronic diseases such as Metabolic syndrome.
Adherence is defined as the extent to which a person's behaviour - taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider. The World Health Organization has estimated that in developing countries, as in Mexico, less than 27% of people with chronic diseases will continue treatment as directed.
Adherence to treatment of chronic disease is a multifactorial problem that includes not only patient-related barriers, but also providers of health services and social security systems themselves. Furthermore, as WHO has pointed out, as increasing prevalence of chronic non-adherence to treatment will become a global problem even more serious.
The purpose of this study is develop and implement a methodology to overcome barriers affecting adherence to treatment of women over 20 years with non-communicable diseases such as metabolic syndrome (diabetes , hypertension and dyslipidemia) evaluating its impact through various quantitative indicators such as weight loss or metabolic syndrome prevalence.
This study will include two phases:
The World Health Organization estimates that worldwide one billion adults are overweight. In Mexico, the prevalence of overweight and obesity using data from 2006 was nearly 70% in men and women over 20 years.
Being overweight is associated with other co-morbidities such as diabetes mellitus (79.4%), hypertension (78.0%) and dyslipidemia (82.8%). WHO has estimated that over 50% of these patients have a poor grip and do not follow their treatment as indicated, generating costs for managing these diseases of until $ 100 billion each year. Improve the effectiveness of interventions on adherence to treatment, will significantly improve the health of these patients and help reduce costs involving health systems.
The obesity and comorbidities affect 41% of the adults in Mexico and increases up to five times the risk of developing cardiovascular disease and type 2 diabetes and up to three times the risk of developing coronary artery disease and myocardial infarction. Therefore, these diseases are currently one of the main problems of public health in Mexico.
Adherence to short and long term is the result of a complex process that develops through different stages: the acceptance of diagnosis, the perceived need for treatment successfully, motivation, and skills training available, the ability to overcome the barriers or difficulties arise, and maintenance of achievements over time.
The lack of adherence to chronic disease is a multifactorial problem that includes not only patient-related barriers, but also with service providers and health systems. Poor adherence to long-term therapies severely compromises the effectiveness of treatment and negatively impacts the quality of life of patients.
It has been observed that the interventions of lifestyle changes that promote weight loss through the practice of physical activity and intake of a hypocaloric diet, reduce the prevalence of Metabolic diseases and achieve a better control.
The changes in lifestyle are the foundation of any strategy for the treatment of chronical diseases . The patients require counseling to effect change in their behavior and improve their risk of mortality and morbidities. So far, interventions to improve treatment of patients with chronic diseases, not including diet and exercise recommendations, has not reported any significant positive change. Moreover, in Mexico there is still no method or reference tool to assess adherence. It has been reported that healthy lifestyles achieve positive changes on cardiovascular risk factors, however, no known methodology to help patients overcome the barriers that prevent them from adopting and adhering to the recommendations that are prescribed providers of health services. Therefore, the objective of this study is to assess if a multidisciplinary treatment that stimulates the constant practice of physical activity and intake of a hypocaloric diet, reduces the prevalence of metabolic chronic diseases such as obesity, diabetes, hypertension and dyslipidemia, and improves the control, in comparison with a traditional medical treatment in Mexican women. Also, to develop a methodology validated in Mexican population to identify barriers that affect adherence to treatment assessing their impact through a variety of quantitative indicators of health.
This project was conducted in 2 phases.
PHASE 1 Development of the tool for identifying barriers. In a private hospital care to chronic noncommunicable diseases, were called patients with co-morbidities associated with overweight and obesity (diabetes mellitus, dyslipidemia, hypertension) to identify common barriers they face to adequately follow through treatment the application of a validated questionnaire. The results will be used as reference for the discussion of traditional treatment algorithms based on the Mexican standards for the management of obesity, hypertension, diabetes and dyslipidemia.
PHASE 2. Design and implementation of the intervention
Phase 2 began with the recruitment of study subjects. The recruitment was done by a local advertising campaign that included posters and leaflets in the city the Cuernavaca, Morelos. México.
Were recruited a group of 180 patients with overweight and two of the following co-morbidities: diabetes mellitus, dyslipidemia or hypertension. All study subjects will be randomized to a control group and intervention. The intervention will last 24 weeks. The control group will receive traditional clinical care and the intervention group will receive a behavioral intervention to improve adherence.
The design of the intervention is based in the the stages-of-change model (also referred to as the transtheoretical model) identifies five stages through which individuals progress as they change behaviours, and stage-matched strategies that predict progress to each subsequent stage of change.
The stages of change are:
Precontemplation at this stage the subject does not plan to make an effort to adhere to treatment or to change your behavior. (Not considering changing behavior in the next 6 months),
The second is called "contemplation", the person admits that there is a risk behavior or beneficial and begin thinking about trying to change or adopt. (Considering changing behavior in the next 6 months),
The third is "preparation" in this stage the person intends to initiate behavior change, strategies and plans to acquire solutions. (Planning to change behavior during the next 30 days),
The fourth is "action" has become the person intended in the expected action (in this study the action is to improve adherence to treatment). (Currently changing behavior)
The fifth is "maintenance", here the change has been established as usual. (Successful behavior change for at least 6 months).
There is a sixth stage called "relapse", where the person returns to the behaviors that had been changed, abandoned the effort and go to the pre-action stages.
Stages of change describe an individual's motivational readiness to change.
The specific tools that contain the intervention program are:
Preparation
At this stage various strategies will be developed:
Action At this stage the individual begins proper actions to get a better adherence It will provide enough printed material that allows it to achieve its goals in diet, physical activity and taking medications.
There will be a computerized database (software) with which you can update the progress and barriers presented by the individual and be able to access either the nutritionist doctor or psychologist
Description of the tools:
In the query are used as reference treatment guidelines of the ADA and the Third Adult Treatment Panel (ATP III).
Data collection will be done with different tools according to the phase of the project
Phase 1:
a) Identification of barriers to treatment through the application of validated questionnaires.
Phase 2:
Variables
Dependent. The dependent variable or outcome will be reduction in the prevalence of obesity and comorbidities (such as hypertension, diabetes, dyslipidemia), and control measured through weight loss, and decrease in blood pressure, fasting glucose, and cholesterol.
Independent. The independent variable is the lifestyle and behavioral program.
Data Analysis. Will present descriptive statistics for the dependent variables weight, fasting glucose, HbA1c, triglycerides, HDL-C, LDL-C, blood pressure and intima-media thickness.
Each group will analyze the mean difference in measurement time (initial, intermediate and final) for mean difference test
The differences between the control and intervention group were analyzed using three strategies: 1) by intention to treat (including patients who dropped out), 2) full support to the intervention (patients who completed the program), and 3) for proper administration of the intervention, ie an analysis will be specific to those subjects who received the intervention effectively by the physician and nutritionist (patients intervened correctly).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
With previous medical diagnosis:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Based on the clinical guidelines of the Ministry of Health, medical treatment was provided and consisted in counseling for chronic diseases such as obesity, hyperglycemia, hypertension, dyslipidemia
1\) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake \<30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.
Behavioral: Healthy lifestyle and adherence
Behavioral intervention to improve adherence to treatment and 1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake \<30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle. The model consists of monthly visits to the doctor, nutritionist and psychologist, for screening cardiometabolic risk factors, to know limitations on treatment adherence, to start intervention to evaluate reasons for success or failure, to evaluate and maintain motivation to adherence to diet, physical activity and medication and long-term care
Reduction in the prevalence of metabolic syndrome (obesity, diabetes, hypertension, dyslipidemia)
To first week(basal), 12 weeks after recruiting (intermediate) and 24 weeks after recruiting (final evaluation)
Time frame: 24 weeks
Reduction of hyperglycemia
To first week(basal), 12 weeks after recruiting (intermediate) and 24 weeks after recruiting (final evaluation)
Time frame: 24 weeks
Weight loss
To first week(basal), 12 weeks after recruiting (intermediate) and 24 weeks after recruiting (final evaluation)
Time frame: 24 weeks
Reduction of high blood pressure
To first week(basal), 12 weeks after recruiting (intermediate) and 24 weeks after recruiting (final evaluation)
Time frame: 24 weeks
Reduction of hypercholesterolemia
To first week(basal), 12 weeks after recruiting (intermediate) and 24 weeks after recruiting (final evaluation)
Time frame: 24 weeks
The record gives a start of Nov 2008, a primary completion of May 2009 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mexican National Institute of Public Health